30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

K2M Reports 2Q16 Revenue -

K2M posted 2Q16 revenue of US $59.2MM, +5.2% vs. 2Q15. (U.S. $45.2MM, +9.2%, ex-U.S. $14.0MM, -6.2%) All growth is as reported.

ORTHOWORLD estimates 2Q16 segment revenue and as reported growth as follows.

  • Spine $27.3MM, +4.9%
  • Orthobiologics $1.9MM, +13.6%


Highlights from 2Q include:

CASCADIA is presently used in 9 countries. More than 200 surgeons use CASCADIA products, and ~50% of them are new to K2M.

The EVEREST Minimally Invasive XT, alpha aunched in 4Q15, was called out as a strong contributor to MIS segment growth. Full commercial launch is slated for late 3Q16.

K2M achieved progress in re-establishing its commercial presence in Australia and Japan following issues announced in 1Q16. Specifically, while sales to the Australia market are down -26% year to date, the company remains committed to Life Healthcare, its Australia distribution partner, based on evidence that it is focused on inventory control and working capital efficiencies.


This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.